---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-23-000065"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T04:26:51.955026+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Neurocrine's crinecerfont Phase 3 pediatric CAH study meets primary, key secondary endpoints

## Summary
- Primary endpoint: statistically significant decrease in serum androstenedione at Week 4 vs placebo (p=0.0002).
- Key secondary: significant reduction in daily glucocorticoid dose while maintaining androgen control at Week 28 vs placebo (p<0.0001).
- About 30% of crinecerfont patients achieved reduction to physiologic GC dose vs 0% placebo.
- Drug generally well-tolerated; common AEs: headache, fever, vomiting, URI, nasopharyngitis.
- Data to support FDA submission in 2024, with EMA submission to follow.

## SEC filing metadata
- accession: 0000914475-23-000065
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447523000065/0000914475-23-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447523000065/nbix-20231005.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-23-000065
- JSON: https://secwatch.observer/filing/0000914475-23-000065.json
- Plain text: https://secwatch.observer/filing/0000914475-23-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.